Gastrointestinal Stromal Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition to paralleling what is already known about c-kit mutations that drive the proliferation of gastrointestinal stromal tumors and their response to imatinib, and providing the possibility of prospectively selecting patients with NSCLC who have a high probability of responding to EGFR TK inhibitors, these reports will likely have much broader implications with regard to the optimal and most expeditious means to develop rationally designed, target-based therapeutic agents--first establishing proof of principle in patients whose malignancies are dependent or driven by aberrations of the therapeutic's target.
|
15638956 |
2004 |
Gastrointestinal Stromal Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The final section will discuss the 4 most mature examples in the GI tract: (1) HER2 testing to select patients with advanced gastroesophageal adenocarcinoma for anti-HER2 therapy, (2) KIT and PDGFRA mutation analysis to direct tyrosine kinase inhibitor therapy in gastrointestinal stromal tumor, (3) DNA mismatch repair function testing to determine the applicability of adjuvant chemotherapy in patients with stage II colorectal cancer (CRC), and (4) KRAS mutation analysis and related testing to determine the appropriateness of anti-EGFR monoclonal antibody therapy in patients with metastatic CRC.
|
24342289 |
2013 |
Gastrointestinal Stromal Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Considered together, the results suggest that ADAM17 may contribute to the progression and growth of GIST through shedding of EGFR ligands and consequent EGFR stimulation.
|
19298600 |
2009 |
Gastrointestinal Stromal Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
On the basis of the involvement of these RTKs in the pathogenesis of these disorders, Ménétrier disease patients have been effectively treated with a blocking monoclonal antibody specific for EGFR and GIST patients with KIT and PDGFRA tyrosine kinase inhibitors.
|
17200708 |
2007 |
Gastrointestinal Stromal Tumors
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Expression of EGFR in some gastric GISTs might be of clinical significance with the recent emergence of EGFR-targeted therapies.
|
18528288 |
2008 |
Gastrointestinal Stromal Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
However, whereas HER2 has been excluded as a therapeutic biomarker, both EGFR and IGF1R are expressed by some wild-type GISTs and are therefore potential therapeutic targets.
|
25659413 |
2015 |
Gastrointestinal Stromal Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We first established that GISTs carrying EGFR mutation are relatively benign tumours.
|
28485054 |
2017 |
Gastrointestinal Stromal Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting c-Kit plus HER1 or AXL/c-Met abrogates IM resistance in GIST.
|
25557174 |
2015 |
Gastrointestinal Stromal Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Selective KIT, PDGFRalpha and epidermal growth factor receptor (EGFR) tyrosine kinase inhibition evolved as powerful targeted therapy for gastrointestinal stromal tumours and non-small-cell lung cancer.
|
18478259 |
2008 |
Gastrointestinal Stromal Tumors
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Variable epidermal growth factor receptor protein immunohistochemical overexpression was detected in 96% of gastrointestinal stromal tumor cases, but none of the 75 cases with represented tumor tissue cores and countable fluorescence signals exhibited epidermal growth factor receptor gene amplification by fluorescence in situ hybridization.
|
17643098 |
2007 |
Gastrointestinal Stromal Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Variable epidermal growth factor receptor protein immunohistochemical overexpression was detected in 96% of gastrointestinal stromal tumor cases, but none of the 75 cases with represented tumor tissue cores and countable fluorescence signals exhibited epidermal growth factor receptor gene amplification by fluorescence in situ hybridization.
|
17643098 |
2007 |
Gastrointestinal Stromal Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression profile of EGFR in gastrointestinal stromal tumors (GISTs) is derived from a limited number of small series samples and case reports.
|
18528288 |
2008 |
Gastrointestinal Stromal Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.
|
19891708 |
2010 |
Gastrointestinal Stromal Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1.
|
28762371 |
2018 |